Trial Profile
An Open-label, Uncontrolled, Single Center, Phase I/II Trial to Assess the Safety and Efficacy of Autologous Hematopoietic Stem Cells Transduced With MT-gp91 Retroviral Vector in gp91 Defective Chronic Granulomatous Disease Patients
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 05 Oct 2022
Price :
$35
*
At a glance
- Drugs VM 106 (Primary)
- Indications Chronic granulomatous disease
- Focus Adverse reactions
- Sponsors Helixmith
- 12 May 2014 New trial record